Product Overview
CJC 1295 is a synthetic growth hormone-releasing hormone (GHRH) analog, and Ipamorelin is a growth hormone-releasing peptide (GHRP). Together, they work synergistically to stimulate the pituitary gland to produce and release growth hormone, supporting recovery, body composition, and overall well-being.
Dosing is individualized based on patient needs. Follow your healthcare provider's specific instructions regarding injection frequency and dosage.
Not recommended for patients with active malignancy or certain medical conditions. Use with caution in patients with a history of pituitary disorders.
May interact with glucocorticoids and other medications affecting growth hormone levels. Inform your healthcare provider of all medications you are taking.
Common side effects may include injection site reactions, headache, flushing, dizziness, and water retention.
Not recommended during pregnancy or breastfeeding without medical supervision.
Store refrigerated at 36°F to 46°F (2°C to 8°C). Protect from light. Reconstituted solution should be used within the specified timeframe.
Contact your healthcare provider for specific questions about CJC 1295 / Ipamorelin therapy.
Related medications
Frequently asked
questions
Our team of experts has the answers you're looking for.
Please contact our customer service team for resources to find healthcare providers familiar with peptide therapy.
Osmolarity information is available on the Certificate of Analysis (COA) for each batch.
We compound many medications beyond what is listed. Please contact us for specific formulations.
All APIs are sourced from FDA-registered facilities with rigorous quality testing.
Ready to get started?
Connect with our team to learn more about our compounding solutions and how we can support your practice.
Contact Us